Journal article
Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients
AJ Thompson, PJ Clark, A Singh, D Ge, J Fellay, M Zhu, Q Zhu, TJ Urban, K Patel, HL Tillmann, S Naggie, NH Afdhal, IM Jacobson, R Esteban, F Poordad, EJ Lawitz, J McCone, ML Shiffman, GW Galler, JW King Show all
Journal of Hepatology | Published : 2012
Abstract
Background & Aims: Interferon-alfa (IFN)-related cytopenias are common and may be dose-limiting. We performed a genome wide association study on a well-characterized genotype 1 HCV cohort to identify genetic determinants of peginterferon-α (pegIFN)-related thrombocytopenia, neutropenia, and leukopenia. Methods: 1604/3070 patients in the IDEAL study consented to genetic testing. Trial inclusion criteria included a platelet (Pl) count ≥80 × 10 9/L and an absolute neutrophil count (ANC) ≥1500/mm 3. Samples were genotyped using the Illumina Human610-quad BeadChip. The primary analyses focused on the genetic determinants of quantitative change in cell counts (Pl, ANC, lymphocytes, monocytes, eosi..
View full abstractGrants
Awarded by National Institute of Allergy and Infectious Diseases
Funding Acknowledgements
This study was funded by Schering-Plough Research Institute, Kenilworth, New Jersey. Dr. Thompson received funding support from the Duke Clinical Research Institute, a generous research gift from the Richard B. Boebel Family Fund, the National Health and Medical Research Council of Australia, the Gastroenterology Society of Australia and the Royal Australasian College of Physicians.r Drs. McHutchison, Goldstein, Muir, Afdhal, Jacobson, Esteban, Poordad, Lawitz, McCone, Shiffman, King, Kwo, Patel and Sulkowski report having received research ad grant support from Schering-Plough. Drs. McHutchison, Goldstein, Muir, Afdhal, Jacobson, Esteban, Poordad, Lawitz, Shiffman, Kwo, and Sulkowski have reported receiving consulting fees or acted in an advisory capacity for Schering-Plough. Drs. Noviello, Pedicone, Brass, Pedicone, and Albrecht are employees of Schering-Plough (now Merck & Co., Inc.) and are stock holders in this entity. Drs. Thompson, Goldstein, McHutchison, Ge, Fellay, Shianna, and Urban are co-inventors of a patent application based on the ITPA finding.